Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $194,937 - $224,786
568 New
568 $201,000
Q1 2022

May 13, 2022

SELL
$254.45 - $351.06 $174,552 - $240,827
-686 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$272.01 - $353.03 $186,598 - $242,178
686 New
686 $240,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Parkwood LLC Portfolio

Follow Parkwood LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkwood LLC with notifications on news.